ABOUT EVENT

Welcome to the inaugural Raw Materials for Cell & Gene Therapy Summit

This summit is a premier gathering of cell and gene therapy raw material experts. This meeting will serve as a pivotal hub for Vice Presidents, Heads and Directors of Raw Materials, Process Development, Quality Control and CMC.

Explore unrivalled opportunities for transparent discussion, open-forum learnings and networking. This summit will provide cell and gene drug developers with tangible action points to reduce costs and development time towards bringing scalable, cost-effective and highly efficacious cell and gene therapies to market to address the unmet clinical need across the globe.

Raw Materials for Cell & Gene Therapy Summit

5 REASONS NOT TO MISS OUT

Establish a unified definition and testing strategy for raw and starting materials to ensure alignment between regulators, drug developers and suppliers with learnings from Genentech & Kiromic BioPharma

Reduce variability by implementing comprehensive strategies to enhance the reliability and consistency of raw material supply with insights from GlaxoSmithKline & Vertex Pharmaceuticals

Standardize raw material quality testing and reduce cost through establishing consistent protocols and procedures with learnings from BlueRock Therapeutics, uniQure & GenSight Biologics

Mitigate safety risks associated with using human-derived raw materials and extractable and leachable considerations for single-use consumables to ensure effectiveness with insights from Cabaletta Bio & Bristol Myers Squibb

Achieve regulatory compliance by streamlining supply chain and GMP manufacturing of your raw materials to develop scalable cell and gene therapies with learnings from Bristol Myers Squibb & Standards Coordinating Body

2024 FULL EVENT GUIDE

Here’s What Some of Our Speakers Have to Say About This Meeting:

“I have not seen a conference or a forum specific to raw materials. This will definitely help companies to interact and gain some exposure to regulatory expectations around raw materials and single-use systems. This will ensure that they are prepared when their product is ready for commercialization” 

Asif Mahmood, Technical Director- Raw Materials, Bristol Myers Squibb

“Raw materials and material qualification is an emerging filed and knowledge sharing is key in the overall success of the cell and gene therapy space.  A lot of suppliers cannot support the needs of the cell and gene therapy raw material quality attributes and establishing a base line for everyone to be on the same page is the beginning” 

Sona Bairamian, Director- Materials Science, Atara Biotherapeutics 
FULL EVENT GUIDE
REGISTER INTEREST
PARTNER